Nutra Pharma Corp. (NPHC)

Market Cap	1.43M +88.5%
Revenue (ttm)	323.13K -24.8%
Net Income	-1.10M
EPS	-0.00
Shares Out	7.16B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	234,100
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0002
52-Week Range	0.000001 - 0.0050
Beta	60.81
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 4, 2026

About Nutra Pharma

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin, an over-the-counter (OTC) pain reliever; Nyloxin Extra Strength, a non-narcotic and non-addictive treatment for severe pain; Pet Pain-Away, an OTC pain reliver for dogs and cats; Equine Pain-Away, an OTC topical pain reliever to relieve pain in horses; and Luxu...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 7
• Stock Exchange: OTCMKTS
• Ticker Symbol: NPHC

Financial Performance

In 2025, Nutra Pharma's revenue was $385,307, a decrease of -1.74% compared to the previous year's $392,150. Losses were -$2.05 million, 59.2% more than in 2024.